Genedrive Share News (GDR)

AIM WINNERS & LOSERS: Genedrive shares jump on orders

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

IN BRIEF: Genedrive shares surge as six countries receive first orders

Genedrive PLC - Manchester, England-based molecular diagnostics company - Says initial orders of its MT-RNR1 products from France, Austria, the Netherlands, Greece, Saudi Arabia and Turkey have been received. News follows confirmation that commercial distribution agreements were signed in multiple countries for Genedrive's test for antibiotic induced hearing loss. Genedrive says these initial orders will support its international distribution partners in promotion and in-country evaluation activities in their respective countries. Hopes this will "provide more extensive access to this life-changing test."

TRADING UPDATES: 600 Group disposal and funding talks continue

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Genedrive shares fall as annual loss widens but focused on investing

(Alliance News) - Genedrive PLC on Thursday reported a widened loss but said it remains focused on investing in product development, focusing on maximising the benefits of its platform.

EARNINGS AND TRADING: Southern Energy loss swing; Craven House widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Genedrive to receive GBP1.2 million grant for test kit

Genedrive PLC - Manchester-based molecular diagnostics company - Confirms that it expects to benefit from GBP1.2 million of funding, through its participation in a multi-partner grant award from Innovate UK and the UK government Innovation Accelerator programme. The grant, which is for the development and validation of technology for time critical genomic testing, will provide Genedrive with acute care patient access and supporting infrastructure to assess the real world clinical performance of time-critical clinical tests in NHS settings.

Genedrive appoints new chief executive and chief scientific officer

(Alliance News) - Genedrive PLC on Monday said it appointed James Cheek as its new chief executive officer, effective immediately.

Genedrive diagnostic test system gets UKCA registration

(Sharecast News) - Point-of-care molecular diagnostics developer Genedrive announced on Wednesday that its Genedrive CYP2C19 System has received UKCA marking registration.

Genedrive shares jump as hails UKCA mark for test; aims for EU CE mark

(Alliance News) - Genedrive PLC on Wednesday said that its CYP2C19 point of care test achieved marking registration in the UK, known as UKCA.

TRADING UPDATES: RTW plans buyback; Octopus AIM VCTs eye fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Genedrive draws down £0.3m under equity prepayment facility

(Sharecast News) - Molecular diagnostics company Genedrive announced the latest drawdown of £0.3m under its £5m equity prepayment facility on Wednesday.

Genedrive secures multi-partner grant award

(Sharecast News) - Molecular diagnostics specialist Genedrive announced its involvement in a multi-partner grant award called DEVOTE on Friday, supported by Innovate UK and the UK government's Innovation Accelerator programme.

AIM WINNERS & LOSERS: Marlowe up on report of potential division sale

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

IN BRIEF: Genedrive shares up as UK government grant received

Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Awarded a multi-partner grant for the validation of its CYP2X19 ID kit from Innovate UK and the UK government Innovation Accelerator programme. Says the 'Devote' grant will allow it to offer critical clinical tests in NHS settings.